KYTX 8-K: Press release furnished with Q3 2025 results update

Rhea-AI Filing Summary

Kyverna Therapeutics, Inc. (KYTX) furnished an 8-K announcing it issued a press release with a business update and financial results for the quarter ended September 30, 2025. The press release is included as Exhibit 99.1.

The company states the information under Item 2.02 and Exhibit 99.1 is furnished, not filed, under the Exchange Act and will not be incorporated by reference into Securities Act or Exchange Act filings unless specifically referenced. The report was signed by Chief Financial Officer Marc Grasso, M.D.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding 8-K Material Events →

Accepted by SEC EDGAR 11/12/2025 - 04:09 PM Learn about SEC filing dates

0001994702false00019947022025-11-122025-11-12

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 12, 2025

Kyverna Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-41947	83-1365441
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
5980 Horton St., Suite 550
Emeryville, California				94608
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (510) 925-2492

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.00001 per share		KYTX		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On November 12, 2025, Kyverna Therapeutics, Inc. (the “Company”) issued a press release providing a business update and reporting financial results for the quarter ended September 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K (the “Current Report”).

In accordance with General Instructions B.2 of Form 8-K, the information in Item 2.02 of this Current Report and Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number		Description
99.1		Press Release issued by Kyverna Therapeutics, Inc. dated November 12, 2025.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		KYVERNA THERAPEUTICS, INC.
Date: November 12, 2025		By:	/s/ Marc Grasso, M.D.
			Marc Grasso, M.D.
			Chief Financial Officer

FAQ

What did Kyverna Therapeutics (KYTX) file?

An 8-K furnishing a press release with a business update and financial results for the quarter ended September 30, 2025.

Which period do the results cover for KYTX?

The quarter ended September 30, 2025.

What exhibit contains the press release for KYTX?

Exhibit 99.1 contains the press release dated November 12, 2025.

Is the information considered filed or furnished?

It is furnished under Item 2.02 and not deemed filed under the Exchange Act.

Will the press release be incorporated by reference?

Only if expressly set forth by specific reference in a future filing.

Who signed the KYTX report?

Marc Grasso, M.D., Chief Financial Officer.

What is the trading symbol and exchange for Kyverna?

KYTX, listed on The Nasdaq Stock Market LLC.